Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-626 in Systemic Lupus Erythematosus
NCT07185269Phase 2Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 626 in systemic lupus erythematosus (SLE), sponsored by 3S Guojian Pharmaceutical. Started Sep 2025; status: recruiting.
02
Drugs
626
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07185269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185269.